Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity.

There are three basic forms of ALD: neonatal, childhood, and adult-onset. Childhood ALD is the classical and the most severe form leading to total disability or death. It affects only boys because the genetic defect is sex-linked (carried on the X-chromosome). The neonatal form affects both male and female infants, progresses rapidly, and may include symptoms such as mental retardation, facial abnormalities, seizures, retinal degeneration, poor muscle tone, enlarged liver, and adrenal dysfunction.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market

The Adrenoleukodystrophy (ALD) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Adrenoleukodystrophy (ALD) market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Adrenoleukodystrophy (ALD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Adrenoleukodystrophy (ALD) Market Key Facts

• In 2017, the total prevalent population of Adrenoleukodystrophy (ALD)  in the 7MM was 55,242.

• In 2017, the prevalent population of Adrenoleukodystrophy (ALD)  in the US was 19,371.

• The estimates show the highest diagnosed prevalence of Adrenoleukodystrophy (ALD) in the United States with 4,885 cases in 2017.

• As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2017–2030).

• Among the European 5 countries, Germany had the highest diagnosed prevalent population of Adrenoleukodystrophy (ALD)  with 1,699 cases, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population of 1,041 in 2017

• Japan ranked second among the 7MM in terms of prevalent cases for Adrenoleukodystrophy (ALD). Japan accounts for approximately 15.82% of total cases, for ALD, in the 7MM countries. In 2017, Japan witnessed 8,739 cases of ALD.

Key Benefits of Adrenoleukodystrophy (ALD) Market Report

• Adrenoleukodystrophy (ALD) market report provides an in-depth analysis of Adrenoleukodystrophy (ALD) Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

• The report will help in developing business strategies by understanding the Adrenoleukodystrophy (ALD) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

• The market report covers the Adrenoleukodystrophy (ALD) current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

• The report provides a detailed assessment of the Adrenoleukodystrophy (ALD) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Adrenoleukodystrophy (ALD) Market

Adrenoleukodystrophy (ALD) market size is expected to increase during the forecast period owing to the Increased number of potential therapies in the pipeline, awareness about newborn screening programs as well as an increase in the number of CALD cases in the 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Adrenoleukodystrophy (ALD) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

 The report gives a thorough detail of the Adrenoleukodystrophy (ALD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

Adrenoleukodystrophy (ALD) Epidemiology

The epidemiology section covers insights about the historical and current Adrenoleukodystrophy (ALD) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Adrenoleukodystrophy (ALD) Epidemiology Segmentation

• Total Prevalent Population of ALD

• Gender-specific Prevalence of ALD

• Gender-specific Diagnosed Prevalent Population of ALD

• Type-specific Diagnosed Prevalence of ALD in males

Adrenoleukodystrophy (ALD) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adrenoleukodystrophy (ALD) market or expected to get launched in the market during the study period. The analysis covers Adrenoleukodystrophy (ALD) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Adrenoleukodystrophy (ALD) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Adrenoleukodystrophy (ALD) market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Adrenoleukodystrophy (ALD) emerging therapies.

Currently, no therapy is approved for the treatment of Adrenoleukodystrophy (ALD), and only off-label therapies used for its management. It is primarily managed by hormone replacement therapy, dietary therapy with Lorenzo’s oil, and Hematopoietic stem cell transplantation. However, many companies at the global level are diligently involved in the development of therapies for Adrenoleukodystrophy (ALD).

Adrenoleukodystrophy (ALD) Companies 

• Bluebird Bio

• Minoryx Therapeutics

• Magenta Therapeutics

And many others.

Adrenoleukodystrophy (ALD) Therapies covered in the report include:

• Lenti-D

• Leriglitazone

• MGTA-456

And many others.

 Table of Content

1. Key Insights

2. Executive Summary 

3. Adrenoleukodystrophy (ALD) Competitive Intelligence Analysis

4. Adrenoleukodystrophy (ALD) Market Overview at a Glance

5. Adrenoleukodystrophy (ALD) Disease Background and Overview

6. Adrenoleukodystrophy (ALD) Patient Journey

7. Adrenoleukodystrophy (ALD) Epidemiology and Patient Population

8. Adrenoleukodystrophy (ALD) Treatment Algorithm, Current Treatment, and Medical Practices

9. Adrenoleukodystrophy (ALD) Unmet Needs

10. Key Endpoints of Adrenoleukodystrophy (ALD) Treatment

11. Adrenoleukodystrophy (ALD) Marketed Products

12. Adrenoleukodystrophy (ALD) Emerging Therapies

13. Adrenoleukodystrophy (ALD) Seven Major Market Analysis

14. Attribute Analysis

15. Adrenoleukodystrophy (ALD) Market Outlook (7 major markets)

16. Adrenoleukodystrophy (ALD) Access and Reimbursement Overview

17. KOL Views on the Adrenoleukodystrophy (ALD) Market.

18. Adrenoleukodystrophy (ALD) Market Drivers

19. Adrenoleukodystrophy (ALD) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market

Latest Reports By DelveInsight
Adrenoleukodystrophy (ALD) Pipeline Insight
Adrenoleukodystrophy (ALD) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Adrenoleukodystrophy (ALD) Market.

Diabetic Eye Disease Market
DelveInsight’s “Diabetic Eye Disease Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diabetic Eye Disease market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/